Alfasigma to expand its digital footprint
AsiaNet 87830
BOLOGNA, Italy, Jan. 28, 2021 /PRNewswire=KYODO JBN/ --
Online doctorAsyou, a web platform entirely dedicated to physicians
The website optimizes research on the most important and autoritative medical
databases such as Pubmed, ICTRP and ClinicalTrials.gov.
An entirely new area presents online courses for physicians on several
different topics
Alfasigma has recently launched a number of digital activities that expand its
web presence and improves its touchpoints around the world.
doctorAsyou – online at www.doctorasyou.com - is a web portal entirely
dedicated to physicians with two main areas: online scientific research and
medical training development.
The Website database optimizes and simplifies online research process of
scientific medical information, for a continuous updating, necessary to face
clinical decisions in the best possible way.
The database is updated daily and returns a total of about 30 million
abstracts, combining the three most authoritative databases in the world such
as PubmedICTRP and ClinicalTrials.gov.
This comprehensive database is able to discover articles and original
researches, keeping users up to date with health and medical developments in
order to stay ahead and improve patient care. It's available also a virtual
library, useful to manage in different folders all saved publication and
search interests. doctorAsyou is focused on first-hand clinical information, in
fact it filteres out non relevant documents types from PubMed (e.g. video,
editorials, books) and improves with other sources.
Pier Vincenzo Colli, CEO of Alfasigma declares: "doctorAsyou is a relevant
investment that Alfasigma has done in favor of the global scientific community
in order to facilitate research work and continuous medical development of
healthcare professionals. It's another important step in our digital
transformation entirely dedicated to serve psysicians and reserarrchers around
the world. The scope goes beyond our focus in gastro-intestinal, vascular and
rheumatological therapeutic areas, because also this project is consistent with
our corporate social responsibility effort to support research and development
in all scientific areas."
The second area is made up with high-level training programs that permit to
advance professional careers and build users' confidence with a 3-6 month
action-oriented learning experience made up of cohort and self-paced courses,
designed and taught by a global experts community. Educational activities are
delivered in a wide variety of formats that are intended to facilitate paying
attention and remembering what is learned. At the same time the courses can be
attended anytime and anywhere. A number of topics are covered such as Writing
in Science, Medication Adherence Definition, Tools, & Statistics, Internet of
Medical Things in Healthcare, Communication Skills For Surgeons, A Data-Driven
Approach to Improve Patient Care and others.
More info.
Pubmed comprises over 30 million citations for biomedical literature from
MEDLINE, life science journals, and online books. PubMed citations and
abstracts include the fields of biomedicine and health, covering branches of
the life sciences, behavioral sciences, chemical sciences, and bioengineering.
ICTRP: International Clinical Trial Registry Platform is a service set up by
the World Health Organisation (WHO) to ensure that information regarding
clinical trials is accessible to all those involved in healthcare decision
making.
Clinicaltrials.gov: it's a database of privately and publicly funded clinical
studies conducted in 50 states and in 216 countries. ClinicalTrials.gov is a
resource provided by the U.S. national Library of Medicine and it includes
around 350,000 research studies.
About Alfasigma
Privately owned, Alfasigma is one of the leading Italian pharmaceutical
companies, present in over 90 countries, through distributors and subsidiaries
and has a workforce of around 3,000 people, R&D laboratories, and 5 production
plants.
In Italy, Alfasigma is a leader in the market for prescription products where,
in addition to the strong focus on gastrointestinal, it is present in many
primary care therapeutic areas. Alfasigma also produces and markets
self-medication products, nutraceuticals and food supplements.
More information is available at the corporate website
Logo - https://mma.prnewswire.com/media/1325576/Alfasigma_Logo.jpg
Source: Alfasigma
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。